

## 2007 Adverse Analytical Findings \* Reported by Accredited Laboratories

### Overview of Results

**Table A** Olympic and Non-Olympic: Adverse Analytical Findings Rate

Differentiation between Olympic and Non-Olympic Sports	A Samples Analyzed	A Sample Adverse Analytical Findings *	% Adverse
Olympic Sports	174,483	3,375	1.93%
Non-Olympic Sports	49,415	1,027	2.08%
<b>TOTAL</b>	<b>223,898</b>	<b>4,402</b>	<b>1.97%</b>

\* **NOTE:** The *Adverse Analytical Findings (AAF)* in this report are not to be confused with adjudicated or sanctioned **Anti-Doping Rule Violations (ADRV)**. "Adverse Analytical Finding" is defined in the World Anti-Doping Code as "a report from a laboratory or other WADA-approved entity that, consistent with the *International Standard for Laboratories* and related Technical Documents, identifies in a *Sample* the presence of a *Prohibited Substance* or its *Metabolites* or *Markers* (including elevated quantities of endogenous substances) or evidence of the *Use of a Prohibited Method*." These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some *Adverse Analytical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in cases of longitudinal studies on testosterone.

**2007 Adverse Analytical Findings \* Reported by Accredited Laboratories**

**Comparison of years 2003 to 2007**

**Table A1**

Olympic and Non-Olympic Statistics

Differentiation between Olympic and Non-Olympic Sports	2003 A Samples Analyzed	2004 A Samples Analyzed	2005 A Samples Analyzed	2006 A Samples Analyzed	2007 A Samples Analyzed	% difference 2007 vs 2006
Olympic Sports	113,559	128,591	139,836	156,866	174,483	11.2%
Non-Olympic Sports	37,651	40,596	43,501	41,277	49,415	19.7%
TOTAL	151,210	169,187	183,337	198,143	223,898	13.0%

Differentiation between Olympic and Non-Olympic Sports	2003 A Samples Adverse Analytical Findings *	2004 A Samples Adverse Analytical Findings *	2005 A Samples Adverse Analytical Findings *	2006 A Samples Adverse Analytical Findings *	2007 A Samples Adverse Analytical Findings *	% difference 2007 vs 2006
Olympic Sports	1,707	2,145	2,958	2,915	3,375	15.8%
Non-Olympic Sports	740	764	951	972	1,027	5.7%
TOTAL	2,447	2,909	3,909	3,887	4,402	13.2%

Differentiation between Olympic and Non-Olympic Sports	2003 % Adverse	2004 % Adverse	2005 % Adverse	2006 % Adverse	2007 % Adverse	% difference 2007 vs 2006
Olympic Sports	1.50	1.67	2.12	1.86	1.93	3.76%
Non-Olympic Sports	1.97	1.88	2.19	2.35	2.08	-11.5%
Overall	1.62	1.72	2.13	1.96	1.97	0.5%

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

**2007 Adverse Analytical Findings \* Reported by Accredited Laboratories**

**Table B** Total Adverse Analytical Findings\* per Laboratory  
(Olympic and Non-Olympic Sports)

Laboratory		N Total	N Adverse Analytical Findings*	% Adverse
1	Sydney, Australia	7,457	134	1.80
2	Seibersdorf, Austria	4,595	94	2.05
3	Ghent, Belgium	6,800	300	4.41
4	Rio de Janeiro, Brazil	5,970	52	0.87
5	Montreal, Canada	15,094	433	2.87
6	Beijing, China	10,202	52	0.51
7	Bogota, Colombia	2,371	73	3.08
8	Havana, Cuba	2,448	71	2.90
9	Prague, Czech Republic	1,826	100	5.48
10	Helsinki, Finland	2,485	60	2.41
11	Paris, France	9,167	461	5.03
12	Cologne, Germany	13,313	269	2.02
13	Kreischa, Germany	6,158	124	2.01
14	London, UK	8,101	73	0.90
15	Athens, Greece	5,019	89	1.77
16	Rome, Italy	10,903	269	2.47
17	Tokyo, Japan	6,099	15	0.25
18	Seoul, Korea	2,833	29	1.02
19	Penang, Malaysia	3,094	68	2.20
20	Oslo, Norway	4,509	91	2.02
21	Warsaw, Poland	2,378	78	3.28
22	Lisbon, Portugal	3,507	92	2.62
23	Bloemfontein, South Africa	2,851	42	1.47
24	Moscow, Russia	8,900	99	1.11
25	Barcelona, Spain	3,365	71	2.11
26	Madrid, Spain	7,183	219	3.05
27	Stockholm, Sweden	4,165	139	3.34
28	Lausanne, Switzerland	5,296	194	3.66
29	Bangkok, Thailand	3,656	34	0.93
30	Tunis, Tunisia	1,934	44	2.28
31	Ankara, Turkey	3,430	13	0.38
32	Los Angeles, USA	38,350	440	1.15
33	Salt Lake City, USA	10,439	80	0.77
<b>TOTAL</b>		<b>223,898</b>	<b>4,402</b>	<b>1.97%</b>

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

**2007 Adverse Analytical Findings \* Reported by Accredited Laboratories**

**Table B1 Olympic Sport Adverse Analytical Findings\* per Laboratory**

Laboratory		N Total	N Adverse Analytical Findings*	% Adverse
1	Sydney, Australia	4,391	69	1.57
2	Seibersdorf, Austria	4,083	83	2.03
3	Ghent, Belgium	5,669	218	3.85
4	Rio de Janeiro, Brazil	5,874	52	0.89
5	Montreal, Canada	14,282	387	2.71
6	Beijing, China	9,670	45	0.47
7	Bogota, Colombia	2,126	54	2.54
8	Havana, Cuba	2,332	65	2.79
9	Prague, Czech Republic	1,489	64	4.30
10	Helsinki, Finland	1,946	48	2.47
11	Paris, France	7,826	383	4.89
12	Cologne, Germany	11,587	210	1.81
13	Kreischa, Germany	5,751	115	2.00
14	London, UK	6,169	47	0.76
15	Athens, Greece	4,614	83	1.80
16	Rome, Italy	9,933	239	2.41
17	Tokyo, Japan	5,294	9	0.17
18	Seoul, Korea	2,212	14	0.63
19	Penang, Malaysia	2,179	26	1.19
20	Oslo, Norway	3,607	74	2.05
21	Warsaw, Poland	2,132	55	2.58
22	Lisbon, Portugal	2,966	67	2.26
23	Bloemfontein, South Africa	1,894	21	1.11
24	Moscow, Russia	8,290	77	0.93
25	Barcelona, Spain	2,930	49	1.67
26	Madrid, Spain	6,224	177	2.84
27	Stockholm, Sweden	3,178	105	3.30
28	Lausanne, Switzerland	4,876	167	3.42
29	Bangkok, Thailand	2,146	24	1.12
30	Tunis, Tunisia	1,782	28	1.57
31	Ankara, Turkey	2,718	12	0.44
32	Los Angeles, USA	21,534	291	1.35
33	Salt Lake City, USA	2,779	17	0.61
<b>TOTAL</b>		<b>174,483</b>	<b>3,375</b>	<b>1.93%</b>

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete such as in the case of longitudinal studies on testosterone.

**2007 Adverse Analytical Findings \* Reported by Accredited Laboratories**

**Table B2 Non-Olympic Sport Adverse Analytical Findings\* per Laboratory**

Laboratory		N Total	N Adverse Analytical Findings*	% Adverse
1	Sydney, Australia	3,066	65	2.12
2	Seibersdorf, Austria	512	11	2.15
3	Ghent, Belgium	1,131	82	7.25
4	Rio de Janeiro, Brazil	96	-	0.00
5	Montreal, Canada	812	46	5.67
6	Beijing, China	532	7	1.32
7	Bogota, Colombia	245	19	7.76
8	Havana, Cuba	116	6	5.17
9	Prague, Czech Republic	337	36	10.68
10	Helsinki, Finland	539	12	2.23
11	Paris, France	1,341	78	5.82
12	Cologne, Germany	1,726	59	3.42
13	Kreischa, Germany	407	9	2.21
15	London, UK	1,932	26	1.35
16	Athens, Greece	405	6	1.48
17	Rome, Italy	970	30	3.09
18	Tokyo, Japan	805	6	0.75
19	Seoul, Korea	621	15	2.42
20	Penang, Malaysia	915	42	4.59
21	Oslo, Norway	902	17	1.88
22	Warsaw, Poland	246	23	9.35
23	Lisbon, Portugal	541	25	4.62
24	Bloemfontein, South Africa	957	21	2.19
25	Moscow, Russia	610	22	3.61
26	Barcelona, Spain	435	22	5.06
27	Madrid, Spain	959	42	4.38
28	Stockholm, Sweden	987	34	3.44
29	Lausanne, Switzerland	420	27	6.43
30	Bangkok, Thailand	1,510	10	0.66
31	Tunis, Tunisia	152	16	10.53
32	Ankara, Turkey	712	1	0.14
33	Los Angeles, USA	16,816	149	0.89
34	Salt Lake City, USA	7,660	63	0.82
<b>TOTAL</b>		<b>49,415</b>	<b>1,027</b>	<b>2.08%</b>

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

2007 Adverse Analytical Findings\* Reported by Accredited Laboratories  
Olympic Sport Sample Analysis

Table C

Sport	Discipline	Total per Discipline	Total per Sport	A Sample Adverse Analytical Findings *	% Adverse
Aquatics	Aquatics	3,867	12,550	154	1.23%
	Diving	301			
	Swimming	7,179			
	Synchronised Swimming	165			
	Water Polo	1,038			
Archery	-	-	1,063	14	1.32%
Athletics	-	-	23,305	304	1.30%
Badminton	-	-	993	9	0.91%
Baseball	-	-	16,971	456	2.69%
Basketball	-	-	8,674	214	2.47%
Biathlon	-	-	1,160	13	1.12%
Bobsleigh	Bobsleigh	780	851	16	1.88%
	Tobogganing	31			
	Skeleton	40			
Boxing	-	-	2,757	87	3.16%
Canoe / Kayak	-	-	3,426	65	1.90%
Curling	-	-	220	9	4.09%
Cycling	Cycling	16,209	16,462	643	3.91%
	Mountain Bike	253			
Equestrian	-	-	878	12	1.37%
Fencing	-	-	2,032	28	1.38%
Football	-	-	28,313	348	1.23%
Gymnastics	Gymnastics	1,959	2,273	31	1.36%
	Artistic Gymnastics	157			
	Rhythmic Gymnastics	63			
	Trampoline	94			
Handball	-	-	3,091	70	2.26%
Hockey	-	-	1,674	28	1.67%
Ice Hockey	-	-	4,385	104	2.37%
Judo	-	-	3,759	45	1.20%
Luge	-	-	280	3	1.07%
Modern Pentathlon	-	-	553	11	1.99%
Rowing	-	-	4,053	66	1.63%
Sailing	-	-	1,306	18	1.38%
Shooting	-	-	2,447	37	1.51%
Skating	Skating	1,805	3,096	27	0.87%
	Speed Skating	891			
	Figure Skating	400			
Skiing	Skiing	2,414	3,844	71	1.85%
	Alpine Skiing	227			
	Cross Country Ski	616			
	Ski Jumping	93			
	Snowboard	283			
	Combined Skiing	53			
	Freestyle Skiing	158			
Softball	-	-	710	3	0.42%
Table Tennis	-	-	853	10	1.17%
Taekwondo	-	-	1,574	16	1.02%
Tennis	-	-	3,050	57	1.87%
Triathlon	-	-	2,657	67	2.52%
Volleyball	Volleyball	3,890	4,136	59	1.43%
	Beach Volleyball	246			
Weightlifting	-	-	6,620	200	3.02%
Wrestling	-	-	3,907	65	1.66%
Baseball / Softball <sup>1</sup>		-	116	9	7.76%
Ice Sport <sup>1</sup>		-	444	6	1.35%
Total			174,483	3,375	1.93%

<sup>1</sup> "Baseball/Softball" and "Ice Sport" were designated on Doping Control Forms and unable to assign by single sport or federation.

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

**2007 Adverse Analytical Findings\* Reported by Accredited Laboratories**

**Table D1** *Sample Analysis in Selected\*\* IOC Recognized Sports*

Sport	Discipline	Total per Discipline	Total per Sport	Adverse Analytical Findings *	% adverse
Rollersports	Roller Hockey	15	468	10	2.14%
	Roller Skating	126			
	Roller Sports	327			
Golf	-	-	513	20	3.90%
Karate	-	-	813	9	1.11%
Rugby <sup>1</sup>	-	-	4,127	67	1.62%
Squash	-	-	358	11	3.07%
<b>TOTAL</b>			<b>6,279</b>	<b>117</b>	<b>1.86%</b>

\*\* as requested by the International Olympic Committee.

<sup>1</sup> Includes *Samples* noted as "Rugby" and "Rugby Union".

**Table D2** *Sample Analysis in Other IOC Recognized Sports*

Sport	Total per Sport	Adverse Analytical Findings *	% Adverse
Air Sports	106	6	5.66%
Bandy	132	4	3.03%
Billiard Sports	282	17	6.03%
Boules	145	4	2.76%
Bowling	228	5	2.19%
Bridge	28	1	3.57%
Chess	73	2	2.74%
Dance Sport	303	2	0.66%
Korfball	101	5	4.95%
Life Saving	172	1	0.58%
Motorcycle Racing	332	13	3.92%
Mountaineering and Climbing	310	6	1.94%
Netball	428	1	0.23%
Orienteering	400	7	1.75%
Pelote Basque	169	6	3.55%
Polo	28	1	3.57%
Powerboating	168	1	0.60%
Racquetball	24	0	0.00%
Sumo	99	0	0.00%
Surfing	75	2	2.67%
Tug of War	133	9	6.77%
Underwater Sports	495	13	2.63%
Water Skiing	203	3	1.48%
Wushu	140	3	2.14%
<b>TOTAL</b>	<b>4,574</b>	<b>112</b>	<b>2.45%</b>

**Table E** *Sample Analysis in Paralympic Sports*

Sport	Total per Sport	Adverse Analytical Findings *	% Adverse
Paralympic Sports	1,519	30	1.97%

\* The *Adverse Analytical Findings* (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some *Adverse Analytical Findings* correspond to multiple measurements performed on the same *Athlete*, such as in the case of longitudinal studies on testosterone.

**2007 Adverse Analytical Findings \* Reported by Accredited Laboratories**

**Table F**                      Number of Substances Identified in Each Drug Class  
(Olympic and Non-Olympic Sports)

Substance Group	Number*	% of all Adverse Analytical Findings
S1. Anabolic Agents	2,322	47.9%
S6. Stimulants	793	16.4%
S8. Cannabinoids	576	11.9%
S3. Beta-2 Agonists	399	8.2%
S5. Diuretics and Other Masking Agents	359	7.4%
S9. Glucocorticosteroids	288	5.9%
S2. Hormones and Related Substances	41	0.8%
P2. Beta-Blockers	27	0.6%
S7. Narcotics	21	0.4%
S4. Agents with Anti-Estrogenic Activity	18	0.4%
M1. Enhancement of Oxygen Transfer	3	0.1%
M2. Chemical and Physical Manipulation	3	0.1%
<b>TOTAL</b>	<b>4,850</b>	

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.



2007 Adverse Analytical Findings\* Reported by Accredited Laboratories

Table G

Substances Identified in Each Drug Class  
(Olympic and Non-Olympic Sports)

S1.1.a. Anabolic Agents - Exogenous AAS	Occurrences	% within drug class
Nandrolone	203	8.7%
Stanozolol	172	7.4%
Methandienone	98	4.2%
Boldenone	40	1.7%
Methyltestosterone	26	1.1%
Metenolone	23	1.0%
Drostanolone	23	1.0%
Oxandrolone	12	0.5%
Mesterolone	11	0.5%
Trenbolone	11	0.5%
Dehydrochlormethyltestosterone	7	0.3%
Mestanolone	7	0.3%
Oxymetholone	4	0.2%
Methasterone	3	0.1%
Clostebol	2	0.1%
Danazol	2	0.1%
Fluoxymesterone	1	0.0%
Prostanozol	1	0.0%
<b>subtotal*</b>	<b>646</b>	

S1.1.b. Anabolic Agents - Endogenous AAS <sup>1</sup>	Occurrences	% within drug class
Testosterone	1,607	69.2%
Prasterone (DHEA)	7	0.3%
6 $\alpha$ -OH-Androstendione	3	0.1%
Etiocholanolone	2	0.1%
Androsterone	2	0.1%
Testosterone precursors	1	0.0%
5-androstendione	1	0.0%
<b>subtotal*</b>	<b>1,623</b>	

S.1.2 Other Anabolic Agents	Occurrences	% within drug class
Clenbuterol	53	2.3%
<b>subtotal*</b>	<b>53</b>	

S.1. All Anabolic Agents	Occurrences
<b>TOTAL *</b>	<b>2,322</b>

<sup>1</sup> Reporting of an Endogenous AAS may be due to detection of a concentration outside normal reference ranges and/or establishment of an exogenous source by GC/C/IRMS.

S2. Hormones and Related Substances	Occurrences	% within drug class
Erythropoetin (EPO)	22	53.7%
Gonadotrophins (hCG)	15	36.6%
Gonadotrophins (LH)	2	4.9%
Erythropoetin (Darbepoetin)	2	4.9%
<b>TOTAL*</b>	<b>41</b>	

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

2007 Adverse Analytical Findings\* Reported by Accredited Laboratories

Table G  
(cont'd)

Substances Identified in Each Drug Class  
(Olympic and Non-Olympic Sports)

S3. Beta-2 Agonists	Occurrences	% within drug class
Terbutaline	182	45.6%
Formoterol	107	26.8%
Salbutamol	60	15.0%
Salmeterol	37	9.3%
Fenoterol	11	2.8%
Reproterol	2	0.5%
<b>TOTAL*</b>	<b>399</b>	

S4. Agents with anti-estrogenic activity	Occurrences	% within drug class
Tamoxifen	6	33.3%
Clomiphene	5	27.8%
Formestane	2	11.1%
6alpha-methylandrosterone	2	11.1%
Androst-1,4,6-triene-3,17-dione (ATD)	2	11.1%
Letrozole	1	5.6%
<b>TOTAL*</b>	<b>18</b>	

S5. Diuretics and other masking agents	Occurrences	% within drug class
Furosemide	111	30.9%
Hydrochlorothiazide	103	28.7%
Finasteride	53	14.8%
Canrenone	15	4.2%
Triamterene	15	4.2%
Epitestosterone	14	3.9%
Amiloride	10	2.8%
Bumetanide	7	1.9%
Chlorothiazide	7	1.9%
Chlortalidone	6	1.7%
Indapamide	4	1.1%
Acetazolamide	4	1.1%
Bendroflumethazide	3	0.8%
Probenecid	3	0.8%
Althiazide	2	0.6%
Spironolactone	1	0.3%
Trimethylchlorothiazide	1	0.3%
<b>TOTAL*</b>	<b>359</b>	

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

2007 Adverse Analytical Findings\* Reported by Accredited Laboratories

Table G  
(cont'd)

Substances Identified in Each Drug Class  
(Olympic and Non-Olympic Sports)

S6. Stimulants	Occurrences	% within drug class
Amphetamine	430	54.2%
Cocaine	101	12.7%
Ephedrine	50	6.3%
Methylphenidate	38	4.8%
Cathine	33	4.2%
Methamphetamine	21	2.6%
Sibutramine	20	2.5%
Clobenzorex	19	2.4%
Modafinil	13	1.6%
Heptaminol	11	1.4%
Phentermine	9	1.1%
4-phenylpiracetam (carphedon)	6	0.8%
Nikethamide	6	0.8%
Isometheptene	6	0.8%
Etilefrine	5	0.6%
Methylephedrine	4	0.5%
Fenetylline	3	0.4%
Fenproporex	3	0.4%
Octopamine	3	0.4%
Strychnine	2	0.3%
Tuaminoheptane	2	0.3%
Pholedrine	2	0.3%
Methylenedioxymethamphetamine	1	0.1%
Norfenfluramine	1	0.1%
Mephentermine	1	0.1%
Phendimetrazine	1	0.1%
Phenmetrazine	1	0.1%
Benzylpiperazine	1	0.1%
<b>TOTAL*</b>	<b>793</b>	

S7. Narcotics	Occurrences	% within drug class
Morphine	19	90.5%
Methadone	1	4.8%
Hydromorphone	1	4.8%
<b>TOTAL*</b>	<b>21</b>	

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

2007 Adverse Analytical Findings\* Reported by Accredited Laboratories

Table G  
(cont'd)

Substances Identified in Each Drug Class  
(Olympic and Non-Olympic Sports)

S8. Cannabinoids	Occurrences	% within drug class
Cannabinoids	576	100.0%
<b>TOTAL*</b>	<b>576</b>	

S9. Glucocorticosteroids	Occurrences	% within drug class
Budesonide	154	53.5%
Betamethasone	42	14.6%
Prednisolone	16	5.6%
Prednisone	7	2.4%
Triamcinolone Acetonide	18	6.3%
Prednisolone + Prednisone	35	12.2%
Methylprednisolone	10	3.5%
Dexamethasone	6	2.1%
<b>TOTAL*</b>	<b>288</b>	

P2. Beta Blockers	Occurrences	% within drug class
Propranolol	8	29.6%
Metoprolol	6	22.2%
Bisoprolol	6	22.2%
Atenolol	3	11.1%
Carvedilol	2	7.4%
Carteolol	1	3.7%
Timolol	1	3.7%
<b>TOTAL*</b>	<b>27</b>	

M1. Enhancement of Oxygen Transfer	Occurrences	% within drug class
Blood Transfusion	3	100.0%
<b>TOTAL*</b>	<b>3</b>	

M2. Chemical and Physical Manipulation	Occurrences	% within drug class
Manipulation	3	100.0%
<b>TOTAL*</b>	<b>3</b>	

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

## 2007 Adverse Analytical Findings\* Reported by Accredited Laboratories

**Table H**

Total Laboratory Adverse Analytical Findings\* vs Drug Class  
(Olympic and Non-Olympic Sports)

Laboratory	S1. Anabolic Agents	S2. Hormones and Related Substances	S3. Beta-2 Agonists	S4. Agents with Anti-Estrogenic Activity	S5. Diuretics and Other Masking Agents	S6. Stimulants	S7. Narcotics	S8. Cannabinoids	S9. Glucocorticosteroids	P2. Beta-Blockers	M1. Enhancement of Oxygen Transfer	M2. Chemical and Physical Manipulation	Total per Lab	% of total Adverse Analytical Findings
Sydney, Australia	92	-	1	-	18	6	2	19	4	-	-	-	142	2.9%
Seibersdorf, Austria	78	-	6	-	4	4	-	7	1	-	-	-	100	2.1%
Ghent, Belgium	108	5	102	1	26	37	6	53	15	-	-	-	353	7.3%
Rio de Janeiro, Brazil	21	1	3	1	8	25	-	2	-	-	-	-	61	1.3%
Montreal, Canada	140	1	18	6	42	218	-	71	14	-	-	2	512	10.6%
Beijing, China	44	-	1	-	5	5	-	2	-	-	-	-	57	1.2%
Bogota, Colombia	61	2	10	-	8	3	1	5	3	-	-	-	93	1.9%
Havana, Cuba	65	-	-	-	5	1	-	-	-	-	-	-	71	1.5%
Prague, Czech Republic	84	1	-	-	8	3	-	10	2	-	-	-	108	2.2%
Helsinki, Finland	44	-	9	-	1	1	-	2	4	1	-	-	62	1.3%
Paris, France	229	5	30	-	38	25	-	106	67	4	2	-	506	10.4%
Cologne, Germany	170	-	26	-	21	25	1	12	15	3	-	1	274	5.6%
Kreischa, Germany	84	2	9	-	7	9	1	2	14	2	-	-	130	2.7%
London, UK	29	1	14	1	1	19	2	13	1	-	-	-	81	1.7%
Athens, Greece	56	-	2	1	5	5	-	6	19	-	-	-	94	1.9%
Rome, Italy	118	8	48	-	16	25	-	42	26	2	-	-	285	5.9%
Tokyo, Japan	3	1	1	-	6	2	-	2	-	-	-	-	15	0.3%
Seoul, Korea	31	-	2	-	2	4	-	-	2	-	-	-	41	0.8%
Penang, Malaysia	52	-	3	-	-	3	-	3	1	6	-	-	68	1.4%
Oslo, Norway	43	-	16	-	4	6	1	8	16	1	-	-	95	2.0%
Warsaw, Poland	92	-	1	1	4	7	2	9	-	-	-	-	116	2.4%
Lisbon, Portugal	45	-	9	-	10	8	-	19	4	2	-	-	97	2.0%
Bloemfontein, S Africa	14	-	1	1	7	6	-	10	4	3	-	-	46	0.9%
Moscow, Russia	85	-	-	-	27	7	1	6	-	-	-	-	126	2.6%
Barcelona, Spain	46	3	12	-	10	10	-	8	6	-	-	-	95	2.0%
Madrid, Spain	124	3	36	-	17	11	3	28	7	-	-	-	229	4.7%
Stockholm, Sweden	80	-	25	1	9	4	-	7	28	-	-	-	154	3.2%
Lausanne, Switzerland	126	3	10	2	10	5	-	11	28	2	1	-	198	4.1%
Bangkok, Thailand	11	-	-	-	10	11	-	3	2	-	-	-	37	0.8%
Tunis, Tunisia	44	-	-	-	6	9	-	3	2	-	-	-	64	1.3%
Ankara, Turkey	6	-	-	-	1	5	-	1	-	-	-	-	13	0.3%
Los Angeles, USA	96	3	2	3	10	229	1	98	3	-	-	-	445	9.2%
Salt Lake City, USA	1	2	2	-	13	55	-	8	-	1	-	-	82	1.7%
<b>TOTAL PER DRUG CLASS</b>	<b>2,322</b>	<b>41</b>	<b>399</b>	<b>18</b>	<b>359</b>	<b>793</b>	<b>21</b>	<b>576</b>	<b>288</b>	<b>27</b>	<b>3</b>	<b>3</b>	<b>4,850</b>	
<b>% of Drug Class</b>	<b>47.9%</b>	<b>0.8%</b>	<b>8.2%</b>	<b>0.4%</b>	<b>7.4%</b>	<b>16.4%</b>	<b>0.4%</b>	<b>11.9%</b>	<b>5.9%</b>	<b>0.6%</b>	<b>0.1%</b>	<b>0.1%</b>		

\* The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. In addition, some Adverse Analytical Findings correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.